Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 + nivolumab versus sunitinib in advanced or metastatic non-clear cell renal cell carcinoma
NL-OMON59005Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zanzalintinib, nivolumab, sunitinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Exelixis, Inc.. Started Nov 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NL-OMON59005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59005.